Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMDW) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Revolution Medicines (RVMDW) over the last 6 years, with Q3 2025 value amounting to 2758.74%.

  • Revolution Medicines' EBIT Margin changed N/A to 2758.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 9074.67%, marking a year-over-year increase of 971066100.0%. This contributed to the annual value of 4207.12% for FY2023, which is 34771100.0% down from last year.
  • As of Q3 2025, Revolution Medicines' EBIT Margin stood at 2758.74%.
  • Revolution Medicines' 5-year EBIT Margin high stood at 2758.74% for Q3 2025, and its period low was 24256.47% during Q4 2023.
  • Moreover, its 4-year median value for EBIT Margin was 722.9% (2022), whereas its average is 2984.36%.
  • As far as peak fluctuations go, Revolution Medicines' EBIT Margin surged by 25481300bps in 2022, and later crashed by -238539400bps in 2023.
  • Over the past 4 years, Revolution Medicines' EBIT Margin (Quarter) stood at 559.33% in 2021, then rose by 28bps to 402.52% in 2022, then crashed by -5926bps to 24256.47% in 2023, then soared by 111bps to 2758.74% in 2025.
  • Its last three reported values are 2758.74% in Q3 2025, 24256.47% for Q4 2023, and 2845.11% during Q2 2023.